Group 1 - ST Unimed (002581.SZ) announced a settlement with Hangzhou Qiangxin Biotechnology Co., resolving a previous equity dispute regarding the 34% stake of its subsidiary, Xiamen Unimed [2][4] - The dispute involved the former chairman of Unimed, Pan Aihua, and Hangzhou Qiangxin's legal representative, Li Pengfei, who were sentenced to several years in prison in February 2024 [2][3] - Hangzhou Qiangxin agreed to transfer the 34% stake in Xiamen Unimed back to Unimed without compensation, while Unimed expressed understanding towards Li Pengfei's alleged embezzlement [2][4] Group 2 - The equity dispute began in May 2022 when Pan Aihua, facing debt issues, signed a deal allowing Hangzhou Qiangxin to acquire the 34% stake for approximately 2.9 billion yuan, which led to a change in control over Xiamen Unimed [3][5] - Unimed later discovered that the 2.9 billion yuan investment by Hangzhou Qiangxin had not been received, and the acquisition was made through an increase in registered capital without actual payment [4] - The court ruled that Hangzhou Qiangxin must return the 34% stake to Unimed, while the criminal responsibilities of the involved parties are still under judicial review [4][5]